Widespread Acceptance and Use of Accuray's Technologies Continue to Grow More than 700 CyberKnife® and TomoTherapy® Systems Have Treated More Than Half a Million Patients Worldwide
SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than half a million patients, further positioning the company as a leader in precise, innovative radiation oncology. To date, the CyberKnife and TomoTherapy Systems have been used in 40 countries to treat patients across the full spectrum of radiation oncology cases including prostate, lung, liver, breast and head and neck cancers.
"The CyberKnife and TomoTherapy Systems are widely recognized by the global oncology community as leading edge, innovative treatment solutions," said Joshua H. Levine, president and chief executive officer of Accuray. "These installation and patient milestones reflect our Systems' continued and growing adoption across the world. Though we are proud of these achievements, there are many more patients that could benefit from the personalized, non-invasive treatment options our technologies provide. We will continue our commitment to maximizing patient access and coverage, while working toward a future where the fear, pain and suffering of cancer are a thing of the past."
"With the ability to image my patients every day I can create highly conformal treatment plans that are more specific to the tumor and can be delivered in fewer doses, thus allowing me to treat indications ranging from breast, liver, pancreatic and head and neck cancers," said Martin Keisch, M.D., president and medical director at Cancer Healthcare Associates in Miami, Florida. "We went live with our TomoTherapy System in December 2012. We have treated more than 200 patients and our system has not been down for more than one hour. The TomoTherapy System has redefined how I deliver radiation treatment."
Accuray's newest innovations are the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems treatment solutions. Between them the entire spectrum of radiation therapy needs are covered. The CyberKnife M6 Series offers the ability to deliver high-quality, high-dose distributions that can be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The TomoTherapy H Series facilitates interactive treatment planning for clinicians to make development of customized plans for a wide range of patients and disease types efficient. The innovative design of the System allows treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.
Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to adoption of new technologies, number of patients treated, clinical experience, clinical applications, clinical results, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated